4//SEC Filing
Schinazi Raymond F 4
Accession 0001209191-19-021848
CIK 0001357874other
Filed
Mar 28, 8:00 PM ET
Accepted
Mar 29, 6:36 PM ET
Size
8.8 KB
Accession
0001209191-19-021848
Insider Transaction Report
Form 4
Schinazi Raymond F
Director
Transactions
- Award
Stock Option (Right to Buy)
2019-03-27+34,544→ 34,544 totalExercise: $16.00Exp: 2029-03-26→ Common Stock (34,544 underlying) - Other
Convertible Promissory Note
2019-03-27$500000.00/sh(indirect: By RFS Partners, LP)Exercise: $13.60→ Common Stock (36,946 underlying)
Footnotes (3)
- [F1]The option vests as to 34% of the underlying shares on March 27, 2020 and vests in equal installments at the end of each successive three-month period over the following 24 months.
- [F2]On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.
- [F3]The 2019 Note is held of record by RFS. RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein.
Documents
Issuer
PRECISION BIOSCIENCES INC
CIK 0001357874
Entity typeother
Related Parties
1- filerCIK 0001397607
Filing Metadata
- Form type
- 4
- Filed
- Mar 28, 8:00 PM ET
- Accepted
- Mar 29, 6:36 PM ET
- Size
- 8.8 KB